Mirum Pharmaceuticals, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $127.8 million for the three months ended June 30, 2025, compared to $77.9 million for the same period in 2024. This represents a 64% increase year-over-year, driven primarily by a surge in product sales, particularly from its lead product, LIVMARLI, which generated $88.2 million in sales, up from $47.2 million in the prior year. For the first half of 2025, total revenue was $239.4 million, a substantial increase from $146.7 million in the first half of 2024.
Despite the revenue growth, Mirum reported a net loss of $5.9 million for the second quarter of 2025, a notable improvement from a loss of $24.6 million in the same quarter of the previous year. The company’s accumulated deficit increased to $664.7 million as of June 30, 2025, up from $644.2 million at the end of 2024. Operating expenses also rose, totaling $132.8 million for the second quarter, compared to $102.1 million in the prior year, largely due to increased research and development costs associated with ongoing clinical trials and commercialization efforts.
Strategically, Mirum has made significant advancements, including the completion of an asset acquisition from Travere Therapeutics in August 2023, which expanded its portfolio of Bile Acid Medicines. Additionally, the company entered into a license agreement with Enthorin Therapeutics for the development of MRM-3379, a compound aimed at treating Fragile X Syndrome, with plans to initiate a Phase 2 clinical trial in late 2025. The company is also actively pursuing geographic expansion, particularly in Japan, where it has partnered with Takeda for the commercialization of LIVMARLI.
Operationally, Mirum has seen increased engagement metrics, with product sales driven by a growing customer base and expanded market presence. The company reported a total of $239.4 million in product sales for the first half of 2025, with significant contributions from both the U.S. and international markets. The company’s employee headcount has also increased as it continues to build its commercial and operational capabilities to support its growth trajectory. Looking ahead, Mirum anticipates continued revenue growth from its approved medicines, although it acknowledges potential fluctuations due to the timing of large orders and variable consideration estimates from its distribution agreements. The company remains focused on advancing its clinical pipeline and expanding its market reach while managing its financial resources prudently.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly cholestatic liver and bile acid disorders. Its core products include LIVMARLI, CHOLBAM, and CHENODAL, targeting conditions like Alagille syndrome, PFIC, and CTX. The company leverages proprietary drug candidates, licensing agreements, and strategic acquisitions to address high unmet medical needs in niche markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.